Uw webbrowser is verouderd

Met een bijgewerkte browser heeft u een betere ervaring met de website van Medtronic. Werk mijn browser nu bij.

×

Skip to main content

CLINICAL EVIDENCE TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI)

   Indications, Safety, and Warnings

LEARN MORE ABOUT THE EVOLUT LOW RISK DATA

LEARN MORE

PATIENT PROSTHESIS 

MISMATCH MATTERS

Calculate your patients risk of prosthesis mismatch

PPM Calculator

LEARN MORE ABOUT THE BICUSPID INDICATION

SEE THE DATA

PROVEN  PLATFORM

Studies demonstrate efficacy of the EvolutTM TAVI Platform.

VIEW DATA
Senior Male

REAL-WORLD  RESULTS

Five-year results demonstrated meaningful treatment for patients with symptomatic severe aortic stenosis.2

VIEW RESULTS

INDUSTRY-LEADING HEMODYNAMICS

At one year, 89% of patients had none/trace PVL.1

SEE STUDY RESULTS

COMPREHENSIVE

CLINICAL evidence

The Medtronic CoreValve™ Evolut™ Platform is supported by a robust body of clinical evidence.

VIEW SUMMARY OF Trials

EXCELLENT  PROCEDURAL OUTCOMES

EvolutTM PRO 30-day results:1

  • 1.7% all-cause mortality
  • 1.7% disabling stroke
  • 11.8% permanent pacemaker

SEE OUTCOMES
1

Williams, et. al, presented at ACC 2018, 1-year outcomes with the EvolutTM PRO Self-Expanding Repositionable Transcatheter Aortic Valve with Pericardial Wrap

2

Gerckens U, Tamburino C, Bleiziffer S, et al. Final 5-year clinical and echocardiographic results for treatment of severe aortic stenosis with a self-expanding bioprosthesis from the ADVANCE Study. Eur Heart J. September 21, 2017;38(36):2729-2738.